Form 4: United Therapeutics EVP & General Counsel Exercises Options, Sells Shares Under 10b5-1 Plan
Insider Transaction Report
Paul A. Mahon, Executive Vice President and General Counsel of United Therapeutics Corporation, exercised stock options and subsequently sold an equivalent number of shares as part of a pre-arranged trading plan.
Summary
- Paul A. Mahon, Executive Vice President and General Counsel of United Therapeutics Corporation, exercised 11,000 stock options at an exercise price of $135.42 per share.
- Concurrently, Mahon sold all 11,000 shares acquired from the option exercise.
- The sales were executed in three tranches at weighted average prices of $303.3063 (3,769 shares), $304.2532 (4,977 shares), and $305.1444 (2,254 shares).
- These transactions were conducted on July 24, 2025, pursuant to a pre-arranged Rule 10b5-1 trading plan established on December 24, 2024.
- Following these transactions, Mahon directly beneficially owns 36,781 shares of Common Stock and 99,000 derivative securities (stock options).
Sentiment
Score: 5
Explanation: Neutral. This is a routine insider transaction under a pre-arranged plan, which is common for executive compensation and personal financial planning. It does not reflect new information about the company's performance or outlook.
Positives
- Execution of a pre-arranged 10b5-1 plan demonstrates structured and compliant insider trading practices.
- The sale price significantly exceeds the option exercise price, indicating a profitable transaction for the insider.
Negatives
- Insider selling, even under a 10b5-1 plan, can sometimes be perceived negatively by some investors, though it is often for personal financial planning purposes.
Future Outlook
NA
Industry Context
This filing details an individual executive's stock transactions and does not provide broader insights into industry trends or competitive dynamics.
Stakeholder Impact
- Minimal impact on shareholders as it represents a routine, pre-planned transaction by an executive for personal financial management, not a signal of company distress or significant new information.
Key Dates
| Date | Description |
|---|---|
| 2023-03-15 | Date stock options became exercisable. |
| 2024-12-24 | Date the Rule 10b5-1 trading plan was entered into. |
| 2025-03-15 | Expiration date of stock options. |
| 2025-07-24 | Date of stock option exercise and subsequent share sales. |
| 2025-07-25 | Date the Form 4 filing was signed. |
Keywords
United Therapeutics, UTHR, SEC Form 4, Insider Trading, Stock Option Exercise, Share Sale, 10b5-1 Plan, Paul A. Mahon, Executive Compensation, Corporate Governance
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.